一氧化氮减少心脏手术后急性肾损伤及3期慢性肾病
该随机对照试验纳入244例择期多瓣膜置换手术患者(多因风湿热),随机接受一氧化氮或氮气,经体外循环气体交换器给予并在术后吸入24小时。主要终点显示,一氧化氮组术后急性肾损伤发生率为50%,对照组为64%(RR 0.78,95%CI 0.62-0.97,P=0.014)。次要终点显示,90天时3期慢性肾病转化率从对照组33%降至治疗组21%(RR 0.64,95%CI 0.41-0.99,P=0.024),1年时从31%降至18%(RR 0.59,95%CI 0.36-0.96,P=0.017)。一氧化氮还降低了30天、90天和1年的总体主要不良肾脏事件。
要点
- 多瓣膜置换且体外循环延长患者,一氧化氮组术后急性肾损伤发生率为50%,对照组为64%(RR 0.78,95%CI 0.62-0.97,P=0.014)。
- 90天时3期慢性肾病转化率:一氧化氮组21% vs 对照组33%(RR 0.64,95%CI 0.41-0.99,P=0.024)。
- 1年时3期慢性肾病转化率:一氧化氮组18% vs 对照组31%(RR 0.59,95%CI 0.36-0.96,P=0.017)。
- 一氧化氮降低30天总体主要不良肾脏事件(RR 0.40,95%CI 0.18-0.92,P=0.016)。
- 一氧化氮降低90天总体主要不良肾脏事件(RR 0.40,95%CI 0.17-0.92,P=0.015)。
适用人群与场景
- 择期行多瓣膜置换手术、需延长体外循环的患者,多数病因为风湿热。
处置流程与药物剂量
- 一氧化氮经体外循环气体交换器给予,并在术后经吸入途径继续给予24小时。
研究设计与关键结果
- 研究类型为随机对照试验,样本量244例,人群为择期多瓣膜置换手术患者(多因风湿热),干预为一氧化氮(治疗组) vs 氮气(对照组),均经体外循环气体交换器给予并在术后吸入24小时。
- 主要终点:术后急性肾损伤发生率一氧化氮组50% vs 对照组64%(RR 0.78,95%CI 0.62-0.97,P=0.014)。
- 次要终点:90天3期慢性肾病转化率一氧化氮组21% vs 对照组33%(RR 0.64,95%CI 0.41-0.99,P=0.024);1年转化率一氧化氮组18% vs 对照组31%(RR 0.59,95%CI 0.36-0.96,P=0.017)。
- 总体主要不良肾脏事件:30天RR 0.40(95%CI 0.18-0.92,P=0.016),90天RR 0.40(95%CI 0.17-0.92,P=0.015),1年RR 0.47(95%CI 0.20-1.10,P=0.041)。
证据类型、等级与局限
- 证据类型:随机对照试验,注册号ClinicalTrials.gov NCT01802619。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于择期多瓣膜置换且体外循环延长的患者,作者认为经体外循环气体交换器及术后吸入一氧化氮24小时可降低术后急性肾损伤、90天和1年3期慢性肾病转化率及30天、90天主要不良肾脏事件。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
RATIONALE: No medical intervention has been identified that decreases acute kidney injury and improves renal outcome at 1 year after cardiac surgery.
OBJECTIVES: To determine whether administration of nitric oxide reduces the incidence of postoperative acute kidney injury and improves long-term kidney outcomes after multiple cardiac valve replacement requiring prolonged cardiopulmonary bypass.
METHODS: Two hundred and forty-four patients undergoing elective, multiple valve replacement surgery, mostly due to rheumatic fever, were randomized to receive either nitric oxide (treatment) or nitrogen (control). Nitric oxide and nitrogen were administered via the gas exchanger during cardiopulmonary bypass and by inhalation for 24 hours postoperatively.
MEASUREMENTS AND MAIN RESULTS: The primary outcome was as follows: oxidation of ferrous plasma oxyhemoglobin to ferric methemoglobin was associated with reduced postoperative acute kidney injury from 64% (control group) to 50% (nitric oxide group) (relative risk [RR], 0.78; 95% confidence interval [CI], 0.62-0.97; P = 0.014). Secondary outcomes were as follows: at 90 days, transition to stage 3 chronic kidney disease was reduced from 33% in the control group to 21% in the treatment group (RR, 0.64; 95% CI, 0.41-0.99; P = 0.024) and at 1 year, from 31% to 18% (RR, 0.59; 95% CI, 0.36-0.96; P = 0.017). Nitric oxide treatment reduced the overall major adverse kidney events at 30 days (RR, 0.40; 95% CI, 0.18-0.92; P = 0.016), 90 days (RR, 0.40; 95% CI, 0.17-0.92; P = 0.015), and 1 year (RR, 0.47; 95% CI, 0.20-1.10; P = 0.041).
CONCLUSIONS: In patients undergoing multiple valve replacement and prolonged cardiopulmonary bypass, administration of nitric oxide decreased the incidence of acute kidney injury, transition to stage 3 chronic kidney disease, and major adverse kidney events at 30 days, 90 days, and 1 year. Clinical trial registered with ClinicalTrials.gov (NCT01802619).
参考来源
- Lei C, Berra L, Rezoagli E, et al. Nitric Oxide Decreases Acute Kidney Injury and Stage 3 Chronic Kidney Disease after Cardiac Surgery. Am J Respir Crit Care Med. 2018. PMID: 29932345. doi:10.1164/rccm.201710-2150OC
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。